Share Price:

APNASPENAspen Pharmacare Hldgs2399638 (0.16%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Regional Overviews

Aspen in Australasia

After Africa, Aspen Australasia is the second largest revenue contributor to Regional Brands, with a comprehensive portfolio of medicines comprising Regional and Global Brands, including prescription and OTC products, as well as Sterile Focus Brands. There is also a manufacturing site in Australia, which produces FDF and undertakes third-party manufacturing.

Key Countries

Australia
New Zealand

Overview

Brand Therapeutic category

Circadin

Hormonal hypnotic sedative

Eltroxin

Thyroid hormone replacement

Maltofer

Iron supplement

Marcaine

Regional and spinal anaesthetic

Xylocaine

Regional anaesthetic

0
Products
Launched

(2022: 8)

Product
Recalls

(2022: Nil)

0 %
Average Staff
Turnover

(2022: 12%)

Work-related
Facilities

(2022: Nil)

30
Sales
Representatives

(2022: 83)

200
Permanent
Employees

(June 2022: 563)

Revenue 2023
R’million
2022 (CER)
R’million
Change
%

Commercial Pharmaceuticals

5 827

5 519

6

Regional Brands

5 150

4 824

7

Sterile Focus Brands

677

695

(3)

Manufacturing – FDF

727
645

13

Total

6 554

6 164

6

Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue is by place of manufacture.

Contribution to Group revenue (%)
Revenue by segment (%)

Source: IQVIA June 2023.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.